Showing results (111-120 of 135) with videos related to
Sort By:
Pageof 14
ACS Medicinal Chemistry Letters|April 16, 2025
Discovery of a Series of Covalent Ligands That Bind to Cys77 of the Von Hippel-Lindau Tumor Suppressor Protein (VHL)Simon C C Lucas, Yong Xu, Sarah Hewitt, et al.Cancer Research|March 31, 2001
Distribution and functional consequences of nucleotide polymorphisms in the 3'-untranslated region of the human Sep15 geneY J Hu, K V Korotkov, R Mehta, et al.Public Health|July 16, 2023
Institutional outbreaks of influenza-like illnesses in the state of São Paulo: an analysis of the epidemiological profile during the COVID-19 pandemicP C C Lucas, C Lorenz, G L Florez-Montero, et al.Cancer Chemotherapy and Pharmacology|January 1, 1996
Intracellular Localization and intercellular heterogeneity of the human DNA repair protein O(6)-methylguanine-DNA methyltransferaseM Belanich, T Randall, M A Pastor, et al.Clinical Pharmacology and Therapeutics|February 20, 2014
Integrating cell-based and clinical genome-wide studies to identify genetic variants contributing to treatment failure in neuroblastoma patientsN Pinto, E R Gamazon, N Antao, et al.Cancer Chemotherapy and Pharmacology|January 29, 1999
Modulation of cyclophosphamide activity by O6-alkylguanine-DNA alkyltransferaseH S Friedman, A E Pegg, S P Johnson, et al.Journal of the American Chemical Society|July 30, 2025
Modular Synthetic Platform for the Elaboration of Fragments in Three Dimensions for Fragment-Based Drug DiscoveryAndres R Gomez-Angel, Hanna F Klein, Stephen Y Yao, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant gliomaH S Friedman, D M Kokkinakis, J Pluda, et al.Journal of Medicinal Chemistry|April 24, 2020
Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding ModeSimon C C Lucas, Stephen J Atkinson, Paul Bamborough, et al.RSC Medicinal Chemistry|November 3, 2022
Fragment screening at AstraZeneca: developing the next generation biophysics fragment setSimon C C Lucas, Ulf Börjesson, Mark J Bostock, et al.Pageof 14